Methods and compositions for determining the responsiveness of cancer therapeutics
AssigneeNew York University
InventorMarie Monaco
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for predicting the responsiveness of a patient to a breast cancer treatment regimen by assaying a biological sample to determine the level of expression of the long-chain fatty acyl-CoA synthetase 4 (ACSL4) in the biological sample. The present invention also provides ACSL4 inhibitors and uses of ACSL4 inhibitors as adjuvant therapies in breast cancer treatment regimens.
Claims52
A method for predicting the responsiveness of a patient to a cancer treatment regimen, said method comprising:
- a. obtaining a biological sample from the patient;
- b. assaying the biological sample for expression of long-chain fatty acyl-CoA synthetase 4 (ACSL4);
- c. quantitating the level of ACSL4 expression in the biological sample;
- d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold;
- and
- c. determining that the patient is responsive to a cancer treatment regimen where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the threshold for determining that the patient is not responsive to a cancer treatment regimen where the level of ACSL4 expression in the biological sample is greater than the level of ACSL4 expression in the control sample or greater than the predetermined threshold level.
A method for identifying whether a breast cancers expresses estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR), said method comprising:
- a obtaining a biological sample from the patient;
- b, assaying the biological sample for expression of ACSL4;
- c. quantitating the level of ACSL4 expression in the biological sample;
- d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold;
- and
- e. determining that the patient is negative for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR) where the level of ACSL4 expression in the biological sample is greater than the level of ACSL4 expression in the control sample or greater than the predetermined threshold level or determining that the patient is positive for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2/neu) and/or androgen receptor (AR) where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the predetermined threshold level.
A method for determining a breast cancer adjuvant treatment regimen for a cancer patient, said method comprising:
- a. obtaining a biological sample from the patient;
- b. assaying the biological sample for expression of ACSL4
- c. quantitating the level of ACSL4 expression in the biological sample;
- d. comparing the level of ACSL4 expression in the biological sample to the level of ACSL4 expression in a control sample or comparing the level of ACSL4 expression in the biological sample to a threshold;
- and
- e. determining a breast cancer adjuvant treatment where the level of ACSL4 expression in the biological sample is less than the level of ACSL4 expression in the control sample or less than the predetermined threshold level.
A method of treating a patient having breast cancer comprising administering a breast cancer therapeutic regimen comprising an ACSL4 inhibitor.
Dependencies are inferred from the claim text.